Gliomas News and Research

RSS

Study identifies PDGFRA as a potential target for pediatric high-grade gliomas

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis.

26 Mar 2025

Yale study unlocks potential of lupus-related antibody to target cold tumors

Yale scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related antibody that can slip, undetected, into "cold" tumors and flip on an immune response that has been turned off by cancer.

25 Mar 2025

New targeted therapy shows early success in treating pediatric high-grade gliomas

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma.

20 Mar 2025

New therapeutic approach shows promise for pediatric high-grade gliomas

Brain tumors remain the most common cause of death from childhood cancer. Paediatric high-grade gliomas (pHGG) in particular are a mostly fatal disease group with a median survival time of less than 18 months after diagnosis and limited treatment options.

14 Mar 2025

Firefighting chemicals leave brain cancer-linked mutations, study shows

Firefighters show higher rates of glioma-linked SBS42 mutational signatures associated with haloalkane exposure, suggesting occupational risk. The study highlights a clear link between firefighting, chemical exposure, and brain cancer mutations.

13 Mar 2025

Already approved drug avapritinib shows promise in treating high-grade gliomas

High-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, incidence of recurrence and difficulty for drugs to cross the blood-brain barrier.

13 Mar 2025

Study investigates genetic mutations linked to occupational exposures

Occupational and environmental exposures can put specific groups of people at higher risk of cancer, including firefighters. A new study by investigators at Mass General Brigham examines a cancer rarely studied in firefighters: gliomas-a type of tumor that forms in the brain or spinal cord.

11 Mar 2025

Study links firefighting chemicals to increased glioma risk

A new study uncovered an association between exposure to chemicals commonly used in firefighting and glioma risk, reinforcing earlier research that has suggested a link between firefighting and the development of cancers.

10 Mar 2025

Glioma mutations more common in firefighters, study reveals

Gene mutations caused by exposure to certain chemical compounds have been linked to the development of gliomas, the most common type of malignant brain tumor.

10 Mar 2025

Neuroscientists win The Brain Prize 2025 for pioneering research into brain cancer

Gliomas are types of cancers that arise in the brain and are extraordinarily difficult to treat. They are the leading cause of brain tumour-related deaths in both children and adults.

5 Mar 2025

Anti-swelling drug may weaken immune system in brain cancer patients

Swelling caused by brain cancer is a serious problem that can lead to serious side effects and even death. While controlling swelling is important, a new study shows that a commonly prescribed anti-swelling drug suppresses the immune system for weeks after dosage, inhibiting the body's ability to fight the cancer.

26 Feb 2025

Early detection of tumor spread improves treatment outcomes

A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University succeeded in the diagnosis of leptomeningeal disease in diffuse midline gliomas by detecting H3K27M-mutant droplets from circulating tumor DNA of cerebrospinal fluid taken from these patients.

27 Jan 2025

Study finds no increased glioma risk with hormone therapy use

It's not easy being a woman. Just look at the statistics. Women are more likely to have such debilitating conditions as osteoporosis, migraines, Alzheimer disease, depression, multiple sclerosis, and brain tumors. Sex hormones are often blamed. However, a new study suggests no link between hormone therapy (HT) and common brain tumors known as gliomas. Results of the study are published online today in Menopause, the journal of The Menopause Society.

15 Jan 2025

Temozolomide and radiation combination improves survival in low-grade glioma patients

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.

25 Nov 2024

Camouflage detection boosts neural networks for brain tumor diagnosis

Research shows that CNNs trained on camouflage detection improve brain tumor classification in MRI scans, highlighting the potential of unconventional training.

21 Nov 2024

Discovery of cyclotide from violets enhances glioblastoma chemotherapy

Glioblastoma is one of the most serious brain diseases known. More than 45% of brain cancers are gliomas.

30 Sep 2024

Innovative CAR-T cells effectively target glioblastoma with reduced toxicity

Glioblastoma is the most common and most aggressive primary brain tumor, with an average survival after diagnosis of less than two years, and against which current treatments remain ineffective.

26 Sep 2024

Hybrid neuron-glia cells found in glioma may impact tumor growth

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital have uncovered a new cell type in the human brain.

5 Sep 2024

CDK4/6 inhibitors show promise for pediatric high-grade glioma treatment

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.

3 Sep 2024

Introducing a blood-based test for minimally invasive detection of IDH1 mutant gliomas

Glioma represents the most common central nervous system cancer in adults. The current classification scheme uses molecular alterations, particularly IDH1.R132H, to stratify lesions into distinct prognostic groups.

30 Aug 2024